Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
5-Amino-1-Methylquinolinium (5-Amino-1MQ)
Also known as: 5-Amino-1-Methylquinolinium, 5A1MQ, NNMT Inhibitor
Confidence
Updated 2026-03-18
5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular metabolism and fat storage. While not a peptide, it is widely marketed alongside peptide therapies for weight management. NNMT is overexpressed in adipose tissue of obese individuals, and its inhibition has shown promising anti-obesity effects in preclinical models. It represents a novel metabolic target.
Class
Metabolic / Weight Management (Small Molecule)
Routes
Oral, Subcutaneous
Half-Life
Not established in humans.
5-Amino-1MQ inhibits NNMT, an enzyme that methylates nicotinamide (vitamin B3) using SAM as a methyl donor. NNMT inhibition increases intracellular NAD+ levels (by preserving nicotinamide for NAD+ synthesis), increases SAM availability (enhancing methylation reactions), activates SIRT1 (NAD+-dependent deacetylase), and shifts adipocyte metabolism toward energy expenditure. In diet-induced obese mice, NNMT inhibition reduced fat mass without affecting food intake.
Half-Life
Not established in humans.
Bioavailability
Oral bioavailability reported in animal models. Not quantified in humans.
No approved indications. Research: obesity/weight management, metabolic syndrome, NAD+ optimization, adipocyte metabolism.
Published preclinical data: NNMT inhibition (using related compounds including 5-amino-1MQ) reduced fat mass in diet-induced obese mice by ~30% without affecting food intake or lean mass. Studies from University of Texas and other labs show NNMT is a validated metabolic target. However, 5-amino-1MQ specifically has limited published data — most NNMT inhibitor research uses earlier tool compounds. No human clinical trial data for any NNMT inhibitor.
Human Studies
0
Animal Studies
10
No human safety data. NNMT is expressed in liver and brain — systemic inhibition could have off-target effects. Theoretical concerns: altered methylation balance, hepatotoxicity (NNMT is highly expressed in liver), neurological effects. Completely unknown risk profile in humans. The molecule is widely sold online with minimal safety characterization.
Investigational. Not a peptide — small molecule NNMT inhibitor. Sold by research chemical and peptide companies without regulatory approval. No IND or clinical trial pathway active.
Drug Interactions: Unknown. Theoretical interactions with methylation-dependent drugs, NAD+ precursors, metabolic medications. Monitoring: No established parameters. Body composition, metabolic markers if used in research context. Research Gaps: Zero human data. Long-term safety of NNMT inhibition. Liver safety. Neurological effects. Translation of mouse obesity data to humans.
Oral (research context — NO validated human protocol)
Common Range
50–150 mg/day (commonly marketed doses — NOT clinically validated)
Timing
Morning, with or without food
Frequency
Once daily
Cycling
4–12 weeks (anecdotal)
Important Note
NOT FDA-approved. NOT a peptide. NO human clinical data. Sold widely online but completely unvalidated for human use. Research compound only.
Connect with a verified provider offering 5-Amino-1MQ therapy near you.
GLP-1 Receptor Agonist
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes and chronic weight management. It represents the leading edge of the incretin-based therapy revolution and has become one of the most widely prescribed peptide therapeutics globally. Available in both injectable (Ozempic, Wegovy) and oral (Rybelsus) formulations.
GH Fragment / Weight Management
AOD 9604 is a modified fragment (amino acids 176-191) of the human growth hormone molecule, designed to retain the fat-burning properties of GH while eliminating its growth-promoting effects. It was originally developed as an anti-obesity pharmaceutical by Metabolic Pharmaceuticals Ltd. in Australia.
Metabolic / Exercise Mimetic
MOTS-c is a 16-amino acid peptide encoded by mitochondrial DNA — making it one of the few known mitochondrial-derived peptides (MDPs) with signaling functions. Often described as an "exercise mimetic," it plays a key role in metabolic regulation, glucose homeostasis, and cellular energy production. It represents a frontier area of peptide research connecting mitochondrial biology to metabolic health.
Metabolic Cofactor
NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme present in every living cell, essential for energy metabolism, DNA repair, sirtuin activation, and cellular signaling. While not a peptide, it is ubiquitously offered by peptide therapy clinics as a peptide-adjacent infusion or injection for anti-aging, cognitive enhancement, and addiction recovery. NAD+ levels decline with age, driving interest in exogenous supplementation.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.